Investors

Complix is backed by a syndicate of experienced life sciences investors. Since its founding in 2008, Complix has raised over €30 million in equity financing (approximately US$35 million).

The most recent financing in 2020 was co-led by LRM (Belgium), Vesalius Biocapital (Luxembourg) and PMV (Belgium). Gemma Frisius Fund, LRD, TrustCapital and management also participated in this round.

Andera Partners
Gemma Frisius Fund
LRM
PMV
TrustCapital
Vesalius Biocapital

Complix Cell Penetrating Alphabodies

A new revolutionary class of therapeutics targeting intracellular targets